Undiscovered Gemz - Mid to Long Holds

[nupapa]

New to this board. Thought I'd share MHTX, which I've been following for more than a decade.

A/S around 500 million O/S around 460 million, so it is getting close to maxed out. However, I'm seeing some very positive signs lately that they may be ready to make some huge announcements related to commercialization. According to their last Quarterly, they expect to have the first commercial cancer detection instrument operating at their facility in Q3 2013. I expect that to be announced sometime soon, which should help move the PPS.

Website and Fully Reporting: http://mhtx.com/investors/sec-filings/

Partners: They already get royalties from a deal with Carpenter Technologies (Ticker: CRS) related to development of nano-titanium. MHTX is contracted to receive a minimum of $9.5 million in royalties from Carpenter during the period 2015-2017. They also are working with Los Alamos Labs and MD Anderson Cancer Research Center.

Investors: They have recently attracted some big time investors, including Chip Mason (formerly of Legg Mason Investments) link: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91449531 and Corky Crovato http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91454434

They also brought in a high profile consultant to help commercialize their cancer detection research: http://ih.advfn.com/p.php?pid=nmona&article=58930089

VERY IMPORTANT OVERVIEW FROM LAST 10Q
Manhattan Scientifics, Inc. (OTCQB: MHTX) www.mhtx.com, is focused on commercialization of disruptive technologies in the nano- medicine space. The company works among the brilliant minds and groundbreaking ideas in the fertile ground of New Mexico – home to two national laboratories, and one of the nation’s highest concentrations of PhD scientists. These technologies are scientifically advanced, but are rarely ready for commercialization.

We have expertise in licensing from the national laboratories and in working with individual inventors. We build intellectual property portfolios and business cases supporting new technologies, and shepherd them to relationships with industrial partners who are well-prepared to launch product. The result is a win for everyone – the lab and inventor see the technology enter the market, the industrial partner gets a solid foundation for a new product, and we profit from building the licensing bridge to industry.

We are currently focused on two opportunities: a nanostructured metals technology, and a nanoparticle-based technology that provides highly sensitive cancer detection. The nanostructured metals technology has been revenue producing for several years. The cancer detection technology can detect cancer years earlier, and is still pre-revenue.

In 2008, we acquired Metallicum Inc., along with its licensed patented nanostructured metals technology. We also licensed additional related intellectual property from Los Alamos National Laboratory, and filed additional patent applications related to the technology. The technology enables metals with uniform, ultrafine grains. This provides greater strength, lighter weight, and enhanced biocompatibility. It provides significant benefits across a wide range of metal applications – anywhere strength or weight is a concern.

In September 2009, we licensed the technology package in a defined field of use to Carpenter Technology Corporation, NYSE:CRS, Fortune/1000. Carpenter plans to aggressively market certain nanostructured ultra-fine grain metals to be mass manufactured under royalty agreements with Manhattan Scientifics. Carpenter has already paid significant fees to Manhattan Scientifics (about $1M/year for the last 4 years) in exchange for limited exclusivity grants made to them. The agreement calls for minimum annual revenues and minimum annual royalties which more than cover the company’s fixed overhead.

MHTX is contracted to receive a minimum of $9.5 million in royalties from Carpenter during the period 2015-2017 of which there is no guaranty.

We are continuing to develop the base technology for application in other fields of use, and are pursuing industrial partners in those other fields, e.g. aluminum, magnesium.

In 2011, we acquired Senior Scientific, LLC, www.seniorscientific.com and its technology for sensitive cancer detection. The technology uses iron oxide nanoparticles and very sensitive magnetic sensors to locate and measure cancer in the body. It can detect cancers 1 million times smaller than current technologies – that’s like the difference between the unaided eye and an electron microscope. It also means detection years earlier – that can be the difference between life and death.

We are currently maturing the technology, and intend to have third party validation in 2014. At that point, we will be ready to enter a strategic partnership or launch product on our own in several different markets.

Senior Scientific is bringing Dr. Edward R. Flynn’s nanomagnetic relaxometry (nanoMRX) from the laboratory to the clinic. nanoMRX can locate and measure tumors one millionth the size detectable by XRays and MRI – that’s like the difference between an electron microscope and the unaided eye. nanoMRX uses non-toxic iron oxide nanoparticles and ultrasensitive magnetic sensors – no XRay radiation, no large and expensive MRI magnets, no injected radioactive isotopes.

Our biggest impact, and largest market, is in human clinical applications. Cancer is estimated to cost the US $1 trillion per year. Many cancers are fatal because they are not caught early enough. We will slash years off the time cancer has to hide and grow untreated. Other cancers are fatal because doctors cannot determine where the cancer has spread, and when therapy has eliminated it all. We will allow doctors to find every tumor site, and monitor the effectiveness of therapy.

Our first human applications are likely to be in the detection of ovarian cancer. Ovarian cancer is the deadliest of gynecological cancers, in part because it stays hidden from current techniques until it has grown to billions of cells and hundreds of sites. Each year in the US, about 15,000 women die from ovarian cancer, and over 20,000 more women are diagnosed with the disease. We are working with Dr. Robert C. Bast Jr. of M.D. Anderson Cancer Center, one of the world’s preeminent researchers in ovarian cancer, to bring nanoMRX to bear on this disease. We are also collaborating with doctors working in breast cancer (230,000 new cases every year) and prostate cancer (240,000 new cases every year).

Bringing nanoMRX to clinical use requires that we demonstrate the technology in animal experiments, and then in clinical trials. Applying nanoMRX to animal experiments reveals an earlier market for us. Millions of animals are used in medical research each year, and this research will benefit from the million-fold increase in sensitivity available from nanoMRX. We are currently developing a commercial instrument for animal measurements. The instrument will be used to generate the preliminary data for the path to clinical use, and will also serve as the basis for product launch into veterinary and research markets. We are scheduled to deliver our cancer diagnostic device to the MD Anderson Small Animal Imaging Facility early next year. Their work will provide important independent validation of the technology, from a key opinion leader in the market.

We are currently building the next generation devices for collaborative use by M.D. Anderson. The technology has been proven in a research prototype instrument funded by the National Institutes of Health. We are currently building the next generation higher performance medical device this year. We expect to have the first commercial instrument operating at our facility Q3 2013. We will use that instrument to further optimize nanoparticles, software tools, and procedures. Results from that instrument will be used to begin marketing to the animal research and veterinary markets, (neither market requires FDA approval) as well as to fuel negotiations with strategic potential partners and prospective acquirers. We intend to place the second instrument in operation at MD Anderson early next year. Our collaborators at MD Anderson are enthusiastic in support, and are already educating their staff about the instrument and beginning to schedule studies.

We are currently funded for the two devices described above. Results from the first instrument at our lab will better position us to engage a strategic partner to launch the product in the animal markets. Validation at MD Anderson early next year will also position us to engage a strategic partner to begin trials targeting the first human applications.


Good Luck,
Nupapa